Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence (AI) workflows across the drug development lifecycle.

These programs apply AI within scientifically grounded modeling workflows and define how next-generation workflows are deployed at scale. The close collaboration between Simulations Plus and leading pharmaceutical organizations will provide direct insight into how AI will be integrated into real-world environments—informing product direction, workflow standardization, and future commercial models. The programs will utilize Simulations Plus' major software platforms, including GastroPlus, MonolixSuite™, ADMET Predictor, and Thales.